Samchundang Pharm announced its plan to start clinical trial on 'oral insulin' within this year. Also the South Korean company explained that four vaccines were added to the pipeline of the 'S-Pass' platform, a technology converting injection into oral drug.

In the case of Eylea (aflibercept) biosimilar, the company expects to complete a global Phase III clinical trial in April next year. With the trial data, the South Korean company is to initiate marketing in the U.S. and Japan from 2023.

On Mar. 25, Samchundang Pharm convened an investor relations event for institutional investors and individual stockholders, and briefed about the S-Pass platform and the progress in Eylea biosimilar c